Welcome to our dedicated page for Aligos Therapeutics news (Ticker: ALGS), a resource for investors and traders seeking the latest updates and insights on Aligos Therapeutics stock.
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical-stage biopharmaceutical company advancing novel therapies for chronic hepatitis B (CHB) and metabolic dysfunction-associated steatohepatitis (MASH). This page aggregates official press releases and verified news about the company’s clinical developments, research breakthroughs, and strategic partnerships.
Investors and industry professionals will find timely updates on ALGS’ pipeline candidates including oral capsid assembly modulators targeting viral suppression in CHB and THR-β agonists addressing liver fat reduction in MASH. The curated news collection provides essential context for understanding clinical trial progress, regulatory milestones, and scientific advancements.
Key content categories include updates on: Phase 1-3 clinical trials, collaborative research initiatives, regulatory communications, and therapeutic mechanism insights. All information is sourced from official company disclosures and reputable industry publications.
Bookmark this page for structured access to ALGS’ evolving scientific narrative. Check regularly for developments in oligonucleotide-based therapies and small molecule candidates progressing through clinical evaluation.
Aligos Therapeutics (Nasdaq: ALGS) announced an expansion of its collaboration with Merck to develop oligonucleotide therapies targeting non-alcoholic steatohepatitis (NASH). This expanded agreement allows Merck to in-license a second NASH target and potentially add a third target in the cardiometabolic space. Aligos will receive payments for these licenses and could earn up to $460 million in milestones plus royalties. The collaboration underscores Aligos' strengths in oligonucleotide research, aiming to create effective therapies for unmet medical needs.
Aligos Therapeutics has announced the discontinuation of its ALG-010133 drug candidate for chronic hepatitis B (CHB) after Phase 1 data indicated insufficient antiviral activity. At the target dose of 400 mg, there was no significant reduction in HBsAg levels. Attempts to evaluate higher doses were deemed unlikely to meet the required efficacy benchmarks. Despite this setback, Aligos emphasizes its robust pipeline, with candidates like ALG-000184 and ALG-020572 still in development, aiming for enhanced functional cure rates in CHB.
Aligos Therapeutics, Inc. (Nasdaq: ALGS) announced that CEO Lawrence M. Blatt will present at the 40th Annual J.P. Morgan Healthcare Conference on January 12, 2022, at 5:15 pm ET. The presentation, conducted virtually, will include a Q&A session. An audio webcast of the presentation will be accessible through the Aligos investor section on their website. Aligos is focused on developing therapeutics for unmet medical needs in viral and liver diseases, particularly targeting chronic hepatitis B and nonalcoholic steatohepatitis.
Aligos Therapeutics (Nasdaq: ALGS) has commenced dosing in healthy volunteers for its Phase 1 trial, Study ALG-055009-301, evaluating its THR-b agonist candidate, ALG-055009, aimed at treating nonalcoholic steatohepatitis (NASH). This cohort study seeks to assess the drug's safety, tolerability, and pharmacodynamics. Dosing in subjects with mild hyperlipidemia is expected to begin in Q1 2022, with topline data anticipated by Q3 2022. NASH currently lacks approved treatments, and Aligos aims to address this significant medical need.
Aligos Therapeutics (Nasdaq: ALGS) has revealed promising new data for its chronic hepatitis B (CHB) treatments at the HEP DART meeting. The Phase 1b study of ALG-000184 demonstrated a high reduction of HBV DNA and RNA in HBeAg-positive patients, similar to results in HBeAg-negative groups. Additionally, preliminary data on a new oral PD-1/PD-L1 antagonist underscores its potential in enhancing immune responses against HBV. Aligos aims to develop a combination therapy approach for functional cures in CHB patients, leveraging various therapeutic candidates.
On November 23, 2021, Vipergen announced a multi-target drug discovery agreement with Aligos Therapeutics (Nasdaq: ALGS). This collaboration utilizes Vipergen's DNA-encoded library (DEL) technology to discover small-molecule compounds targeting specific proteins developed by Aligos for treating viral and liver diseases. Aligos will maintain exclusive rights for global commercialization of any resulting products. Financial details remain undisclosed, but Vipergen aims to enhance Aligos' drug portfolio, addressing critical health needs in chronic hepatitis B, NASH, and coronavirus.
Aligos Therapeutics (Nasdaq: ALGS) announced that Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO, will present at the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 30 to December 2, 2021. The presentation will be available as a webcast starting November 22, 2021, at 10:00 AM EST, with a replay accessible for 90 days. Aligos management will also hold virtual investor meetings during the conference. For more details, visit the Aligos website or contact your Piper Sandler representative.
Aligos Therapeutics, Inc. (Nasdaq: ALGS) announced the appointment of Dr. Bridget Martell to its board of directors. Dr. Martell brings extensive experience in therapeutics development, having contributed to six marketed products and held leadership roles in various biopharmaceutical companies. CEO Lawrence Blatt emphasized her role in advancing Aligos's therapeutic candidates for chronic hepatitis B and NASH through clinical trials. Aligos aims to be a leader in treating viral and liver diseases with innovative therapies.
On November 15, 2021, Aligos Therapeutics announced that CEO Lawrence M. Blatt will present at the Jefferies London Healthcare Conference on November 18-19, 2021. The company, listed on Nasdaq under the ticker ALGS, focuses on developing innovative treatments for viral and liver diseases. A webcast of the presentation will be available starting November 18, 2021, at 8:00 AM GMT with a replay accessible for 30 days. Interested investors can schedule virtual one-on-one meetings through their Jefferies representatives.
Aligos Therapeutics (Nasdaq: ALGS) announced significant advancements in its hepatitis B virus (HBV) treatment pipeline at The Liver Meeting 2021. The company presented promising results for its capsid assembly modulator (CAM) candidate, ALG-000184, which showed rapid reductions in HBV DNA and RNA after 28 days of oral dosing. Aligos also highlighted the synergistic potential of its multi-modal approach to enhance treatment effectiveness for chronic hepatitis B (CHB). Additionally, preclinical findings on several candidates, including STOPS™ and ALG-055009, demonstrated favorable pharmacokinetic profiles.
FAQ
What is the current stock price of Aligos Therapeutics (ALGS)?
What is the market cap of Aligos Therapeutics (ALGS)?
